TriangleAromatase inhibitors or tamoxifen (NCT06361940)
Aromatase inhibitors or tamoxifen trial for Breast Cancer (NCT06361940). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with untreated stage I or II invasive, hormone-receptor-positive, HER2-negative breast cancer and no clinical lymph-node involvement. They must qualify for preoperative endocrine treatment.
The idea: use an aromatase inhibitor to reduce estrogen production, or tamoxifen to block estrogen’s effect on cancer cells. Treatment lasts roughly 4–12 weeks before surgery. Researchers compare tumor markers before and after treatment to study endocrine resistance; drug choice depends on medical history and menstrual status.
This phase 2 study plans 185 patients. Lubna Chaudhary leads in Milwaukee, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.